Read the article that Tinker posted about generic drugs and "market failures." Pay particular attention to the various classes of drug customers that the author enumerates. (You'll probably understand it a lot better than I do.) However, having said that, I have serious doubts that the author's analyses of previous generic drug launches are applicable to the Lovenox situation. For a number of reasons, I think Sandoz is in a much more favorable position than the cases of previous generic drug launches that the author cites.
Market Data 
Markets 
AI
